Mr. Tabrizi is Managing Director of Pandect Bioventures. Previously, he served as CFO of ShangPharma Innovations. Prior to joining SP Innovation he held executive-level positions in corporate business development at Nektar Therapeutics, and in investor relations and corporate communications roles at Depomed. He also held key positions in healthcare investment banking at Needham & Co., RBC Capital Markets and Merrill Lynch, and served as CFO at Alacritas (Omnicare). In these roles, Mr. Tabrizi led numerous deals spanning the range of royalty monetization, out-licensing and in-licensing, manufacturing and supply, collaborations and partnerships, mergers and acquisitions, and public and private financings including roadshows and venture investments.
Mr. Tabrizi holds a bachelor’s degree in molecular genetics from University of California, Davis; a master’s degree in biological sciences from Stanford University; and an MBA from the S.C. Johnson Graduate School of Management at Cornell University.